Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review

  • Wan Y
  • Heneghan C
  • Perera R
 et al. 
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


BACKGROUND: To date, there has been no systematic examination of the relationship between international normalized ratio (INR) control measurements and the prediction of adverse events in patients with atrial fibrillation on oral anticoagulation. METHODS AND RESULTS: We searched MEDLINE, EMBASE, and Cochrane through January 2008 for studies of atrial fibrillation patients receiving vitamin-K antagonists that reported INR control measures (percentage of time in therapeutic range [TTR] and percentage of INRs in range) and major hemorrhage and thromboembolic events. In total, 47 studies were included from 38 published articles. TTR ranged from 29% to 75%; percentage of INRs ranged from 34% to 84%. From studies reporting both measures, TTR significantly correlated with percentage of INRs in range (P

Author-supplied keywords

  • *Anticoagulants/ae [Adverse Effects]
  • *Atrial Fibrillation/dt [Drug Therapy]
  • 0 (Anticoagulants)
  • 12001-79-5 (Vitamin K)
  • Administration, Oral
  • Anticoagulants/ad [Administration & Dosage]
  • Atrial Fibrillation/di [Diagnosis]
  • Atrial Fibrillation/pp [Physiopathology]
  • Blood Coagulation/de [Drug Effects]
  • Clinical Trials as Topic
  • Hemorrhage/pc [Prevention & Control]
  • Humans
  • Prognosis
  • Time Factors
  • Vitamin K/ai [Antagonists & Inhibitors]

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

  • PMID: 20031794


  • Y Wan

  • C Heneghan

  • R Perera

  • N Roberts

  • J Hollowell

  • P Glasziou

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free